GlassScriptPhysician profile
Jessica Boado
NPI 1932499464
$4,724.70
in general payments reported to CMS, 2019-2025
32 companies · $838 in 2025
The $838 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $981 · 2022: $695 · 2023: $1,030 · 2024: $1,181 · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,048.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,064.22 | 2021-2025 | Xifaxan, Trulance |
| Amgen INC. | $453.58 | 2021-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $294.63 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $274.01 | 2023-2025 | Voquezna |
| Novo Nordisk INC | $269.73 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $267.26 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $260.36 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $243.94 | 2021-2025 | Verquvo |
| Redhill Biopharma INC. | $203.31 | 2021-2024 | Talicia, Aemcolo, Movantik |
| Pfizer INC. | $196.09 | 2021-2025 | |
| Qol Medical, LLC | $112.34 | 2024-2025 | Sucraid, Sucraid |
| Actelion Pharmaceuticals US, INC. | $106.58 | 2024-2025 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $95.00 | 2022-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $93.68 | 2021-2023 | Farxiga |
| Lexicon Pharmaceuticals, INC. | $88.54 | 2023-2024 | Inpefa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $86.34 | 2021-2023 | |
| Alfasigma USA, INC. | $82.08 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $78.58 | 2022-2025 | Eliquis |
| Janssen Biotech, INC. | $69.66 | 2024-2025 | Tremfya |
| Medicomp INC | $56.99 | 2025 | Telepatch Cardiac Monitor |
| Sanofi Pasteur INC. | $53.48 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.27 | 2025 | |
| Boston Scientific Corporation | $35.79 | 2021 | |
| Madrigal Pharmaceuticals | $26.31 | 2025 | Rezdiffra |
| Lundbeck LLC | $26.00 | 2025 | Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $25.66 | 2024 | Entyvio |
| Aimmune Therapeutics, INC. | $22.95 | 2024 | |
| Bardy Diagnostics, INC. | $21.34 | 2022 | |
| Evoke Pharma, INC. | $19.76 | 2024 | |
| Esperion Therapeutics, INC. | $16.00 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $14.15 | 2024 | Sureclip |
| Vistapharm, INC. | $14.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Boado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.